Arcera Life Sciences has outlined its long-term strategy to connect medical innovation from Asia with patients across international markets, highlighting partnerships, regulatory collaboration and local manufacturing capabilities at the Abu Dhabi Future Health Summit 2026.
Following the integration of five businesses under a unified operating model over the past two years, the company is focusing on three key priorities: innovation, patient access and capability development. Its growing portfolio spans neuroscience, cardiometabolic care, rare diseases and oncology, supported by partnerships with Fosun Pharma, Daewoong and AriBio.
Also read: New Multispecialty Hospital in Bahrain to Create More Than 200 Healthcare Jobs
“Ultimately, our strategy is about combining innovation with the capabilities and reach needed to translate it into meaningful outcomes for patients,” said Isabel Afonso, Chief Executive Officer, Arcera Life Sciences.
The company currently serves patients in more than 100 markets, directly and through partners, with a portfolio of over 2,000 medicines. It is also exploring opportunities with M42 through a memorandum of understanding focused on genomic insights, clinical development and next-generation therapies, including cell and gene therapies.
Looking ahead to 2030, Arcera aims to expand patient access, strengthen local capabilities and contribute to Abu Dhabi’s development as a global life sciences hub.
Sunil Bhilotra, Chief Investment Officer, Arcera Life Sciences, said “The company looks for credible partners with differentiated medicines in its focus areas, ideally first-in-class or best-in-class therapies. “Quality is non-negotiable,” he said, noting that every asset undergoes rigorous scientific, clinical and regulatory due diligence, and Arcera’s manufacturing and quality network across eight countries operates to international standards.”
